| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Nanrilkefusp alfa | SO-C101; RLI-15; CYP-0150; SOT-101 | Phase 2 Clinical | Microsatellite instability-high cancer; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Prostatic Neoplasms, Castration-Resistant; Thyroid Diseases; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details | |
| MB-107 | IND-14570; MB-107 | Phase 2 Clinical | St Jude Children's Research Hospital, National Institute Of Allergy And Infectious Diseases (Niaid), National Heart, Lung And Blood Institute, National Institute of Health, Islamabad | X-Linked Combined Immunodeficiency Diseases; Immunologic Deficiency Syndromes | Details |
| GI-101 | SIM-323; SIM323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| Pegenzileukin | THOR-707; SAR-444245 | Phase 2 Clinical | Synthorx Inc | Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Esophageal adenocarcinoma; Oropharyngeal Neoplasms; Intestinal Neoplasms; Multiple Myeloma; Mesothelioma; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
| REGN-7257 | REGN-7257 | Phase 2 Clinical | Anemia, Aplastic | Details | |
| IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Urinary Bladder Neoplasms | Details |
| TransCon IL-2 β/γ | Phase 2 Clinical | Ascendis Pharma A/S | Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| TYF-IL-2Rg gene-modified autologous stem cells (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | X-Linked Combined Immunodeficiency Diseases | Details | |
| Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details |
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
| NL-201 (Neoleukin Therapeutics) | NL-201 | Phase 1 Clinical | Neoleukin Therapeutics Inc | Solid tumours | Details |
| Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |




